Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2003

View Archived Issues

Interaction of unfractionated heparin and aspirin with YM-337 after infusion in healthy subjects

ViroPharma presents three series of antipicornavirus agents

Cathepsin K inhibitors under study at Novartis

Novel PPARalpha agonists identified by Aventis researchers

Merck presents new tyrosine kinase inhibitors for cancer and other angiogenesis-related disorders

Solvay claims new NK2 antagonists with utility in irritable bowel syndrome therapy

Alizyme scientists describe novel lipase inhibitors for obesity and related disorders

Grant supports development of CEL-1000 for viral encephalitis

Insulin detemir offers improved predictability and control in basal bolus insulin therapy

Second phase I study of OGX-011 begins

Elidel approved in Switzerland

Approvable letter for Vitrase

HE-2100 protects nonhuman primates from effects of radiation exposure

Epimmune's EP HIV-1090 vaccine candidate taken into phase I trials

Recent findings on angiolytic Exherin

Obese patients enrolled in new phase IIb trial for BVT-933

Frovatriptan launched in U.K.

FDA approves Factive for respiratory tract infections

Protein Design Labs completes acquisition of Eos Biotechnology

Rat studies with AZD-3582 indicate good efficacy and GI tolerability

Pharmacokinetic/pharmacodynamic modeling for proton pump inhibitor YH-1885

Chymase inhibitor shows potential in preventing aortic aneurysmal dilatation

Successful treatment of fibromyalgia with tizanidine

Improvement in metabolic syndrome upon chronic treatment with adenosine receptor antagonist

Better safety profile found for etoricoxib compared to indomethacin in acute gouty arthritis

SAR reported at ACS meeting in a series of ranolazine analogues

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...